Trastuzumab Deruxtecan (Enhertu)
Canadian Journal of Health Technologies · 13.03.2026 · 6 (3)
DOI: 10.51731/cjht.2026.1380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.03.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses trastuzumab deruxtecan (Enhertu), powder for concentrate for solution for IV infusion (infusion/100 mg/vial). Indication: Proposed: For treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least 1 endocrine therapy in the metastatic setting.
Zitieren
APA
CDA-AMC (2026). Trastuzumab Deruxtecan (Enhertu). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1380
Vancouver
CDA-AMC. Trastuzumab Deruxtecan (Enhertu). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1380
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Trastuzumab Deruxtecan (Enhertu)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {3},
doi = {10.51731/cjht.2026.1380}
}
EUVIMED